Intec Pharma (NTEC) Rating Reiterated by Oppenheimer
A number of other research analysts have also weighed in on the company. HC Wainwright set a $16.00 price objective on Intec Pharma and gave the company a buy rating in a report on Sunday. Zacks Investment Research lowered Intec Pharma from a hold rating to a sell rating in a report on Friday, March 16th. Finally, Ladenburg Thalmann Financial Services started coverage on Intec Pharma in a report on Wednesday, February 28th. They set a buy rating on the stock. Two analysts have rated the stock with a sell rating and six have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $12.00.
Shares of NTEC stock remained flat at $$6.30 during mid-day trading on Wednesday. 11,825 shares of the company’s stock were exchanged, compared to its average volume of 109,775. Intec Pharma has a 52-week low of $4.80 and a 52-week high of $9.80.
TRADEMARK VIOLATION NOTICE: This story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/intec-pharma-ntec-rating-reiterated-by-oppenheimer/1956488.html.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.